CJEU Opinion Backs Lundbeck Fine Over Citalopram ‘Pay For Delay’ Deals
Fine Of Almost €94m Should Be Upheld, Advocate General Recommends
A CJEU advocate general has backed a European Commission fine of almost €94m imposed on Lundbeck over “pay for delay” deals struck with four generics firms over citalopram.
You may also be interested in...
In the wake of the European Commission issuing Teva with a supplementary statement of objections over a historical “pay for delay” patent settlement agreement on modafinil with Cephalon, the Israeli firm has insisted on its right to reply.
The UK’s Competition and Markets Authority has welcomed a formal ruling by the CJEU that settling patent disputes can break EU law by restricting competition and abusing a dominant position, in a case revolving around so-called ‘pay for delay’ settlements over GSK’s Seroxat paroxetine antidepressant.
Patent-litigation settlements reached almost 20 years ago in the UK over GSK’s Seroxat paroxetine antidepressant may contravene EU competition law, an advocate general has advised the CJEU.